Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2026-09-11 18:12:13 ET · period of report 2026-09-10 · accession 0001873905-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-11 18:12 | 2026-09-10 | CADL | Tak Paul Peter | CEO, Dir | M - OptEx | $1.55 | +125.0K | 393.6K | +47% | +$193.8K |
| DMT | 2026-09-11 18:12 | 2026-09-10+ | CADL | Tak Paul Peter | CEO, Dir | S - Sale+OE | $11.28 | -280.2K | 113.3K | -71% | -$3.16M |
| DT | 2026-09-11 18:12 | 2026-09-10 | CADL | Tak Paul Peter | CEO, Dir | M - OptEx | $0.00 | -125.0K | 1.64M | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-10 | M | A | 125,000 | $1.55 | 393,566 | D | — | — | (F1) This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026. |
| 2 | Common | Common Stock | 2026-09-10 | S | D | 220,866 | $11.50 | 172,700 | D | — | — | (F1) This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein. |
| 3 | Common | Common Stock | 2026-09-11 | S | D | 59,379 | $10.46 | 113,321 | D | — | — | (F1) This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-09-10 | M | D | 125,000 | $0.00 | 1,638,968 | D | $1.55 · — to 2030-10-10 | 125,000 Common Stock | (F1) This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026. (F4) 25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |